First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor

Mise à jour : Il y a 4 ans
Référence : NCT01156870

Femme et Homme

Extrait

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR566658 Secondary Objectives: - To characterize the safety profile of SAR566658 - To evaluate the pharmacokinetic profile of SAR566658 - To assess the potential immunogenicity of SAR566658 - To assess preliminary antitumor activity - To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam - To assess safety in the alternative schedules of SAR566658 administration


Critère d'inclusion

  • Neoplasm malignant

Liens